Palovarotene: First Approval.

Abstract

Palovarotene (Sohonos™) is an orally bioavailable selective retinoic acid receptor (RAR)γ agonist being developed by Ipsen for the reduction of heterotopic ossification (HO) formation in patients with fibrodysplasia ossificans progressiva (FOP). By binding to RARγ, palovarotene inhibits bone morphogenetic protein and SMAD 1/5/8 signalling: interfering with these pathways prevents chondrogenesis and ultimately HO by permitting normal muscle tissue repair or regeneration to occur. Palovarotene received its first approval on 21 January 2022 to reduce the formation of HO in adults and children aged 8 years and above for females and 10 years and above for males with FOP in Canada. This article summarizes the milestones in the development of palovarotene leading to this first approval.

• Authors: Sheridan M Hoy
• Journal: Drugs (Drugs) Vol. 82 Issue 6 Pg. 711-716 (Apr 2022) ISSN: 1179-1950 [Electronic] New Zealand
• PMID: 35384641 (Publication Type: Journal Article, Review)
• Copyright: © 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Chemical References

• Pyrazoles
• Stilbenes
• Palovarotene

Topics

• Adult
• Child
• Female
• Humans
• Male
• Myositis Ossificans (drug therapy, metabolism)
• Ossification, Heterotopic (metabolism)
• Pyrazoles (pharmacology)
• Stilbenes (pharmacology)